New Genetic Links to Osteoarthritis Uncovered in Sheffield Research
A recent study in Sheffield has revealed over 900 genetic connections related to osteoarthritis, among which around 500 were previously unreported. This research is being hailed as a significant global advancement in understanding the degenerative disease.
According to the Sheffield Teaching Hospitals NHS Foundation Trust, this study is the largest of its kind, addressing a condition that impacts approximately 595 million individuals worldwide, making it a leading cause of disability and chronic pain.
The genome analysis utilized genetic data from nearly two million participants and was published in the journal Nature.
Conducted by Helmholtz Munich, Germany’s premier scientific research institution, the study compared genetic codes of around half a million osteoarthritis patients — including a thousand volunteers from Sheffield — to those of 1.5 million individuals without the disease.
Researchers identified 962 genetic variations that were more prevalent among those with osteoarthritis, surpassing 500 previously unknown variations. Alarmingly, projections estimate the number of osteoarthritis patients could reach a billion by 2050. Despite its widespread impact, there are currently no disease-modifying treatments available.
Yet, the team’s findings may lead to potential new drug therapies and individualized treatment options. As Prof. Mark Wilkinson, an Honorary Consultant Orthopaedic Surgeon at the trust and the University of Sheffield, stated, the discoveries are “hugely important” and could pave the way for exciting new possibilities for millions of affected individuals.
Prof. Wilkinson added that beyond identifying potential drug targets, this research enhances our grasp of the biological mechanisms that underpin the disease. The study uncovered eight biological processes crucial for regulating internal bodily functions, shedding light on these mechanisms. Notably, some identified genes produce proteins already targeted by medications approved for other diseases, which might help speed up the development of new treatments.
